gip/glp-1 agonist Frontiers GLP1-GIP receptor co-agonists: a promising
Description
Due to its sizable patient population with obesity and associated disorders such as type 2 diabetes and cardiovascular diseases, the United States in particular holds a significant portion of the market
Because they are new, patented drugs, GLP-1s can cost more than $1,000 per month at their list price
Severe GI reactions can happen with Wegovy
Dillon JS, Tanizawa Y, Wheeler MB, Leng XH, Ligon BB, Rabin DU, Yoo-Warren H, Permutt MA, and Boyd AE, 3rd
doi:10.2337/db18-0317 12
To view a copy of this licence, visit About this article Cite this article Lin, S., Deng, Y., Huang, J
